Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05743036 |
TitleZN-c3 in Adult Participants With BRAF mutant Metastatic Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2023-02-24 |
地点
California, United States
Kansas, United States Texas, United States 澳大利亚 德国 Hungary 意大利 波兰 西班牙 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
cetuximab, encorafenib, ZN-c3 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05759728 |
Title针对转移性结直肠癌受试者的 CNA3103（LGR5 靶向自体 CAR-T 细胞）研究 | 阶段
第 1 阶段
|
Date Added 2023-03-08 |
地点
澳大利亚
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05714553 |
TitleNUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | 阶段
Phase 1, Phase 2
|
Date Added 2023-02-06 |
地点
英国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Docetaxel, Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab |
标签
MSI-H/ MMRd
|
| NCT ID NCT05426005 |
TitleCadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer | 阶段
Phase 1, Phase 2
|
Date Added 2022-06-21 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Cadonilimab |
标签
MSI-H/ MMRd
|
| NCT ID NCT05653882 |
TitleA Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | 阶段
第 1 阶段
|
Date Added 2022-12-16 |
地点
California, United States
Connecticut, United States Florida, United States Massachusetts, United States Michigan, United States Missouri, United States New Jersey, United States New York, United States North Carolina, United States Tennessee, United States Virginia, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05464030 |
TitleAnti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | 阶段
第 1 阶段
|
Date Added 2022-07-19 |
地点
California, United States
Rhode Island, United States Texas, United States 加拿大 日本 大韩民国 西班牙 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
M9140 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05198934 |
Title索托拉西布和帕尼单抗与研究者选择治疗克氏鼠肉瘤（KRAS）p.G12C 突变患者（代码 300） | 阶段
第三阶段
|
Date Added 2022-01-20 |
地点
Alabama, United States
California, United States District of Columbia, United States Florida, United States Georgia, United States Michigan, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States 澳大利亚 法国 德国 希腊 意大利 日本 大韩民国 墨西哥 西班牙 台湾 英国 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05349890 |
TitlePersonalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) | 阶段
第 1 阶段
|
Date Added 2022-04-27 |
地点
Oregon, United States
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
CDX-1140, Pembrolizumab, Keytruda |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05350917 |
TitleStudy of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy | 阶段
第二阶段
|
Date Added 2022-04-28 |
地点 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
尚未招聘
|
药物
Tislelizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05409417 |
TitleExploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status | 阶段
第二阶段
|
Date Added 2022-06-08 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
Unknown status
|
药物
Bevacizumab, cetuximab, FOLFOX, Tislelizumab, XELOX |
标签
MSS/ MMRp
|
